Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
Observational · No treatment assigned · 1 site · Imelda GI Clinical Research Center
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Crohn Disease (CD) and Ulcerative Colitis (UC). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 16 and older
- Any sex
Some of the main requirements, copied from the record:
- ≥18 years
- Patient with confirmed diagnosis of IBD
- Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice
Plus 1 more requirement(s). There are also 4 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 100 participants are expected to take part.
- Start date: 2026-05-01.
- Main results expected around 2026-12-31 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Belgium.
Main thing being measured
- Correlation between LRG serum level and endoscopic disease activity in CD and UC (Day 1)
In the researchers’ words
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Crohn Disease (CD); Ulcerative Colitis (UC) |
| Lead sponsor | Imelda GI Clinical Research Center |
| Enrollment | 100 (estimated) |
| Start date | 2026-05-01 |
| Primary completion (est.) | 2026-12-31 |
| First posted | 2026-06-02 |
| Last updated | 2026-06-02 |
| Official title | Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context: LEADER Trial. |
| ClinicalTrials.gov ID | NCT07621783 |
Interventions
- Leucine-rich α2-glycoprotein (Diagnostic Test)
Leucine-rich α2-glycoprotein measurement
Full eligibility criteria (from the record)
Inclusion Criteria: 1. ≥18 years 2. Patient with confirmed diagnosis of IBD 3. Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice 4. willing to provide informed consent Exclusion Criteria: 1. Patient with IBD unspecified 2. Patient with ileo- or colostomy 3. Patient with total colectomy 4. Women that are pregnant
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Imelda General Hospital | Bonheiden | Belgium | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.